BR9909978A - Pharmaceutical composition for parenteral administration, process for treating a patient suffering from hemophilia, and use of a colloidal particle - Google Patents

Pharmaceutical composition for parenteral administration, process for treating a patient suffering from hemophilia, and use of a colloidal particle

Info

Publication number
BR9909978A
BR9909978A BR9909978-0A BR9909978A BR9909978A BR 9909978 A BR9909978 A BR 9909978A BR 9909978 A BR9909978 A BR 9909978A BR 9909978 A BR9909978 A BR 9909978A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
parenteral administration
protein
hemophilia
treating
Prior art date
Application number
BR9909978-0A
Other languages
Portuguese (pt)
Inventor
Moshe Baru
Liliana Bar
Israel Nur
Original Assignee
Opperbas Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opperbas Holding Bv filed Critical Opperbas Holding Bv
Publication of BR9909978A publication Critical patent/BR9909978A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide and substantially neutral colloidal particles. The particles comprise approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer which carriers substantially no net charge. The protein or polypeptide is capable of externally binding the colloidal particles, or is capable of binding polyethylene glycol, and is not encapsulated in the colloidal particles. A preferred protein is factor VIII, whose half-life is extended and which is protected from serum inhibitor antibodies by injecting it as a component of the composition.
BR9909978-0A 1998-04-27 1999-04-23 Pharmaceutical composition for parenteral administration, process for treating a patient suffering from hemophilia, and use of a colloidal particle BR9909978A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12422498 1998-04-27
PCT/IL1999/000217 WO1999055306A1 (en) 1998-04-27 1999-04-23 Pharmaceutical composition comprising factor viii and neutral liposomes

Publications (1)

Publication Number Publication Date
BR9909978A true BR9909978A (en) 2000-12-26

Family

ID=11071435

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909978-0A BR9909978A (en) 1998-04-27 1999-04-23 Pharmaceutical composition for parenteral administration, process for treating a patient suffering from hemophilia, and use of a colloidal particle

Country Status (12)

Country Link
US (2) US6593294B1 (en)
EP (1) EP1079805B1 (en)
JP (1) JP4545928B2 (en)
AT (1) ATE283034T1 (en)
AU (1) AU747391B2 (en)
BR (1) BR9909978A (en)
CA (1) CA2329768C (en)
DE (1) DE69922189T2 (en)
ES (1) ES2233036T3 (en)
MX (1) MXPA00010241A (en)
PT (1) PT1079805E (en)
WO (1) WO1999055306A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043665A2 (en) * 2000-11-30 2002-06-06 The Research Foundation Of State University Of New York Ahf associated dispersion system and method for preparation
US7625584B2 (en) * 2000-11-30 2009-12-01 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
US8110218B2 (en) * 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
DE60335469D1 (en) * 2002-07-02 2011-02-03 Univ Texas RADIOACTIVELY MARKED COMPOUNDS AND LIPOSOME AND THEIR MANUFACTURING AND APPLICATION METHOD
US7351688B2 (en) * 2003-02-05 2008-04-01 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
ES2307009T3 (en) * 2003-04-15 2008-11-16 Opperbas Holding B.V. PHARMACEUTICAL COMPOSITION CONTAINING PROTEINS AND / OR COLOID POLYPEPTIDES AND PARTICLES.
CA2534565C (en) 2003-08-05 2012-06-19 The Research Foundation Of State University Of New York Reconstitution medium for protein and peptide formulations
WO2005079185A2 (en) * 2003-09-02 2005-09-01 Board Of Regents, The University Of Texas System Neutral liposome-encapsulated compounds and methods of making and using thereof
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US8182834B2 (en) * 2004-01-23 2012-05-22 Camurus Ab Ternary non-lamellar lipid compositions
WO2006053299A2 (en) 2004-11-12 2006-05-18 Bayer Healthcare Llc Site-directed modification of fviii
WO2006113679A2 (en) * 2005-04-15 2006-10-26 Board Of Regents, The University Of Texas System Delivery of sirna by neutral lipid compositions
EP1898939A2 (en) * 2005-06-29 2008-03-19 The Research Foundation of State of University Of New York at Buffalo Compositions and methods for less immunogenic pr0tein-lip1d complexes
WO2007021822A2 (en) 2005-08-09 2007-02-22 The Research Foundation Of State Of University Of New York At Buffalo Compositions and methods of preparation of liposomal microparticulate il-12
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US7875288B2 (en) * 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
AU2007235463B2 (en) * 2006-03-30 2012-11-22 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
DK2101821T3 (en) 2006-12-15 2014-10-06 Baxter Healthcare Sa Factor VIIA (poly) sialic acid conjugate with extended half-life in vivo
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
KR101648734B1 (en) 2008-06-24 2016-08-18 체에스엘 베링 게엠베하 Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
US8877242B2 (en) 2008-07-14 2014-11-04 Polypid Ltd. Sustained-release drug carrier composition
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
AU2010272167B2 (en) 2009-07-14 2016-11-17 Polypid Ltd. Sustained-release drug carrier composition
EP2470287A4 (en) 2009-08-28 2015-01-21 Univ Columbia Systems, methods, and devices for production of gas-filled microbubbles
US10010709B2 (en) 2009-12-16 2018-07-03 The Trustees Of Columbia University In The City Of New York Composition for on-demand ultrasound-triggered drug delivery
US20130028959A1 (en) 2009-12-16 2013-01-31 Massachusetts Institute Of Technology Liposomes for Preventing the Spread of HIV
WO2011089595A2 (en) 2010-01-19 2011-07-28 Polypid Ltd. Sustained-release nucleic acid matrix compositions
US8637448B2 (en) * 2010-09-14 2014-01-28 University Of Rochester Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface
DE102010043733A1 (en) 2010-11-10 2012-05-10 Oxprotect Gmbh Unloaded PEGylated liposomes for use as medicaments for the prophylaxis and therapy of hemorrhagic and thromboembolic disorders
EP2814502B1 (en) 2012-02-15 2017-09-13 CSL Behring GmbH Von willebrand factor variants having improved factor viii binding affinity
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
DK3164150T3 (en) 2014-07-02 2021-02-08 CSL Behring Lengnau AG MODIFIED BY WILLEBRAND FACTOR
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
US11155601B2 (en) 2015-03-06 2021-10-26 CSL Behring Lengnau AG Modified von Willebrand factor having improved half-life
EP3298036B1 (en) 2015-05-22 2022-04-06 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
JP6573989B2 (en) 2015-05-22 2019-09-11 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト A truncated von Willebrand factor polypeptide for the treatment of hemophilia
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
SG11201805497QA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
SG10201912857XA (en) 2016-01-07 2020-02-27 CSL Behring Lengnau AG Mutated von willebrand factor
WO2017220099A1 (en) 2016-06-24 2017-12-28 Statens Serum Institut Adjuvants with modified drainage properties
WO2018005657A1 (en) * 2016-06-28 2018-01-04 Verily Life Sciences Llc Serial filtration to generate small cholesterol-containing liposomes
JP2020504082A (en) 2016-11-11 2020-02-06 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト Truncated von Willebrand factor polypeptide for extravascular administration in the treatment or prevention of blood clotting disorders
DK3538133T3 (en) 2016-11-11 2021-04-19 CSL Behring Lengnau AG TRUNKED VON WILLEBRAND FACTOR POLYPEPTIDES FOR THE TREATMENT OF HEMOPHILIA

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7900459A (en) 1979-01-19 1980-07-22 Hendrik Coenraad Hemker Prof D PHARMACEUTICAL PREPARATION AND METHOD OF PREPARATION THEREOF.
JPS56127307A (en) * 1980-03-11 1981-10-06 Green Cross Corp:The Blood-coagulation factor 8 pharmaceutical for oral administration
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU7217891A (en) * 1990-02-13 1991-09-03 Oxford Virology Plc Therapeutic agents, and intermediates for the synthesis thereof
US6326353B1 (en) 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method

Also Published As

Publication number Publication date
AU747391B2 (en) 2002-05-16
ATE283034T1 (en) 2004-12-15
WO1999055306A1 (en) 1999-11-04
EP1079805B1 (en) 2004-11-24
CA2329768C (en) 2008-06-10
DE69922189T2 (en) 2005-11-10
US6930087B2 (en) 2005-08-16
JP2002512947A (en) 2002-05-08
DE69922189D1 (en) 2004-12-30
PT1079805E (en) 2005-03-31
US20030134778A1 (en) 2003-07-17
MXPA00010241A (en) 2004-09-06
CA2329768A1 (en) 1999-11-04
ES2233036T3 (en) 2005-06-01
AU3441499A (en) 1999-11-16
US6593294B1 (en) 2003-07-15
JP4545928B2 (en) 2010-09-15
EP1079805A1 (en) 2001-03-07

Similar Documents

Publication Publication Date Title
BR9909978A (en) Pharmaceutical composition for parenteral administration, process for treating a patient suffering from hemophilia, and use of a colloidal particle
FI971776A (en) Compounds and compositions for the administration of active substances
FI962154A0 (en) Composition for in vivo preparation of therapeutic products
DE69312947T2 (en) PROTEIN-BASED MEDICINES WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES
ATE383169T1 (en) COMPONENT AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE INGREDIENTS
BR9714015A (en) Pharmaceutical formulations for prolonged drug delivery
HK1014156A1 (en) Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant
DE69823055D1 (en) DELIVERY OF POLYETHYLENE GLYCOL MOLECULE CONJUGATES FROM DEGRADABLE HYDROGEL
RU94006023A (en) Physiologically active composition on the base of lyophilized, modified by polyalkylene oxide complexes of protein and peptide with cyclodextrin and method for its production
IS5087A (en) Stable liquid interferon preparations
DE69533855D1 (en) INTERRUPTION OF BINDING OF PROTEINS MDM2 AND P53 AND CORRESPONDING THERAPEUTIC APPLICATION
DE59809588D1 (en) MEDICINE SUPPORT PARTICLES FOR TISSUE-SPECIFIC MEDICINE APPLICATION
WO1998026747A3 (en) Superantigen based methods and compositions for treatment of diseases
AU5956398A (en) Remedies for lymphocytic tumors
EP0422125A4 (en) Platelet blocking peptides
TR200102107T2 (en) Tumor necrosis factor antagonists and their use in endometriosis.
DE69408122D1 (en) COMPOSITION OF MICROPARTICLES IN THE COMPRESSED PHASE AND METHOD
BRPI0409424A (en) pharmaceutical composition for parenteral administration, method of treating a patient suffering from hemophilia, use of a colloidal particle, and method of treating a patient suffering from a disease
DE69932113D1 (en) Pharmaceutical compositions of hedgehog proteins and their use
GB2428241B (en) Polymeric materials
ATE483816T1 (en) SYSTEMIC VIRUS/LIGAND GENE DELIVERY AGENT AND GENE THERAPY

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: ZILIP PHARMA B.V. (NL)

Free format text: TRANSFERIDO DE: OPPERBAS HOLDING B.V.

B12B Appeal against refusal [chapter 12.2 patent gazette]